Tubular breast cancer is not strongly driven by inherited genetics in most cases. It accounts for only 1 to 2% of all invasive breast cancers, and while there are some genetic links worth understanding, the majority of people diagnosed with this subtype do not carry a known hereditary mutation. That said, the tumor itself has a distinct genetic profile that sets it apart from more common breast cancers, and there is a modest connection to one inherited gene in particular.
The BRCA2 Connection
Of the two well-known breast cancer genes, BRCA2 has the more notable relationship with tubular carcinoma. Research into hereditary breast cancers has found an excess of tubular and lobular carcinomas among people with BRCA2 mutations compared to those with BRCA1 mutations. This doesn’t mean tubular cancer is a hallmark of BRCA2 carriers, but it does appear more frequently in that group than you’d expect by chance.
BRCA1 mutations, by contrast, tend to produce aggressive, triple-negative breast cancers, which are biologically very different from tubular carcinoma. Tubular tumors are almost always hormone receptor positive, HER2 negative, and slow-growing, placing them in a completely different molecular category.
Family History Plays a Small Role
When researchers have looked at whether a family history of breast cancer raises the risk of developing the tubular subtype specifically, the association has been weak. Some studies have found a slight link, but it’s far less pronounced than the family history connections seen with more common forms of breast cancer. In practical terms, most people diagnosed with tubular carcinoma do not have a strong family pattern of breast cancer driving their diagnosis.
Current guidelines from the American Society of Breast Surgeons recommend that genetic testing be offered to all patients with a personal history of breast cancer, regardless of the specific subtype. So even though tubular carcinoma alone doesn’t trigger special genetic testing protocols, you should still have the opportunity to be tested if you’ve been diagnosed. This can help clarify your risk for future cancers and inform screening decisions for family members.
How Tubular Tumors Differ Genetically
While inherited mutations play a limited role, the tumor cells themselves carry a distinctive genetic fingerprint. Compared to the more common invasive ductal carcinomas, tubular cancers have significantly fewer chromosomal changes overall. They do, however, show a much higher rate of losing a piece of chromosome 16 (called 16q loss) and a lower rate of losing part of chromosome 17. These differences are statistically significant enough that researchers consider tubular carcinomas a genetically distinct group of breast cancers, not just a well-behaved version of standard invasive ductal carcinoma.
At the molecular level, tubular cancers fall into the luminal A or luminal B subtypes. They typically show strong, uniform estrogen receptor positivity, with progesterone receptor positivity in roughly 69 to 75% of cases. HER2 is usually negative, and the proliferation rate (how fast the cells divide) tends to stay below 10%. This molecular profile is a big part of why tubular carcinoma behaves so differently from other invasive breast cancers.
What This Means for Prognosis
The genetic makeup of tubular carcinoma translates directly into its favorable outlook. The 5-year disease-free survival rate generally exceeds 90%, and the 10-year overall survival rate is comparable to that of the general population. These numbers reflect the slow-growing, low-grade nature of these tumors.
For a tumor to be classified as pure tubular carcinoma, pathologists look for at least 75 to 90% of the tissue to be arranged in the characteristic tube-shaped structures. Mixed tubular carcinomas, which contain a lower percentage of tubular architecture, have historically been considered slightly less favorable, though recent studies suggest outcomes are similar for both pure and mixed forms.
Should You Worry About Passing It On?
If you’ve been diagnosed with tubular breast cancer, the chance that you’re carrying a hereditary mutation responsible for it is relatively low compared to someone diagnosed with triple-negative or high-grade breast cancer at a young age. But “relatively low” isn’t zero, and the BRCA2 association is real. Genetic testing can give you a definitive answer, and since guidelines now support testing for anyone with a breast cancer diagnosis, there’s no reason not to pursue it if you want clarity.
For family members wondering whether a relative’s tubular breast cancer diagnosis changes their own risk, the key factors remain the same ones that matter for any breast cancer: the number of affected relatives, the ages at which they were diagnosed, and whether any known mutations run in the family. A single case of tubular carcinoma in a relative, without other risk factors, does not substantially change the risk picture.